Adding abiraterone acetate (ZYTIGA) to androgen deprivation therapy for the management of patients with metastatic castration-naïve prostate cancer does not increase medical resource utilization.
The decline occurred despite a consistent number of monthly clinical encounters with a primary diagnosis of hypogonadism.
Active surveillance as an initial management strategy for men with low-risk prostate cancer results in cost savings compared with immediate treatment, regardless of the treatment chosen.
A minority of patients are involved in shared decision-making about prostate cancer screening with PSA, but new strategies to incorporate shared decision-making into practice are being investigated.
Long-term use of a multivitamin may protect against recurrence of prostate cancer, particularly in those men who have had radical prostatectomy.
Enzalutamide (XTANDI) with androgen deprivation therapy delays the development of metastatic disease in men with M0 castration-resistant prostate cancer compared with ADT alone, according to results from the randomized phase III PROSPER study.
An immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) extended overall survival compared with sunitinib (SUTENT) as first-line treatment of patients with advanced or metastatic renal cell carcinoma.
A bladder-sparing approach for the treatment of muscle-invasive bladder cancer increases quality-adjusted life years compared with radical cystectomy in appropriately selected patients.
About one-fourth of patients with interstitial cystitis/bladder pain syndrome have Hunner lesions in the bladder visible on cystoscopy.
Repeated hydrodistention as therapy for interstitial cystitis has a low complication rate and does not decrease bladder capacity over time.